Literature DB >> 15724500

Does antiphospholipid antibody syndrome affect bioprosthetic heart valve? Midterm echocardiographic report.

Shunei Saito1, Hiroshi Ikeguchi, Harumitsu Yamamoto, Akira Koike, Kazuo Yamaguchi, Eiji Takeuchi.   

Abstract

Cardiovascular involvements in antiphospholipid antibody syndrome have been recognized as a major complication of this disease. Furthermore, some papers report bioprosthetic heart valve also seems to be affected. A 32-year-old female with aortic regurgitation presented to our hospital. Further examination revealed high titer of anticardiolipin beta 2 glycoprotein 1 antibody, and she was diagnosed as having primary antiphospholipid antibody syndrome since the patient failed to match the criteria of systemic lupus erythematosus. Cardiopulmonary bypass was uneventfully conducted under systemic heparinization of usual dosage. Administration of warfarin sodium was started on the third postoperative day, and international normalized ratio was controlled from 2.0 to 2.5. On echocardiographic examination at 1 month, mean systolic gradient was 17 mmHg. Although transesophageal echocardiography at 2 years after surgery revealed no sign of valvular destruction or sclerosis, transaortic gradient had increased to 26 mmHg. Bioprosthetic stenosis was suspected probably due to pannus formation and the patient may have to undergo another valve replacement in the near future.

Entities:  

Mesh:

Year:  2005        PMID: 15724500     DOI: 10.1007/s11748-005-1006-6

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  8 in total

1.  Secondary mitral valve replacement in antiphospholipid syndrome and chronic renal failure.

Authors:  Y Kato; F Isobe; Y Sasaki; H Kumano; K Nagamachi; H Arimoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-12

2.  [A case report on mitral valve replacement associated with antiphospholipid syndrome in systemic lupus erythematosus].

Authors:  Y Araki; K Tajima; T Shimomura; T Abe; M Yoshikawa; A Io; T Tuzuki; Y Suenaga
Journal:  Kyobu Geka       Date:  1997-06

Review 3.  Clinical and therapeutic aspects of the antiphospholipid syndrome.

Authors:  P R Ames; M A Khamashta; G R Hughes
Journal:  Lupus       Date:  1995-02       Impact factor: 2.911

4.  Aortic valve replacement for aortic regurgitation in a patient with primary antiphospholipid syndrome.

Authors:  K Matsuyama; Y Ueda; H Ogino; T Sugita; K Matsubayashi; T Nomoto; S Yoshimura; T Yoshioka
Journal:  Jpn Circ J       Date:  1999-09

5.  Early experience with the mosaic bioprosthesis: a new generation porcine valve.

Authors:  S P Wong; M E Legget; S C Greaves; B G Barratt-Boyes; F P Milsom; P J Raudkivi
Journal:  Ann Thorac Surg       Date:  2000-06       Impact factor: 4.330

6.  Antiphospholipid antibody syndrome with involvement of a bioprosthetic heart valve.

Authors:  A Niaz; J Butany
Journal:  Can J Cardiol       Date:  1998-07       Impact factor: 5.223

7.  Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery.

Authors:  Yackov Berkun; Amir Elami; Karen Meir; Dror Mevorach; Yaakov Naparstek
Journal:  J Thorac Cardiovasc Surg       Date:  2004-02       Impact factor: 5.209

Review 8.  Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome.

Authors:  M Hojnik; J George; L Ziporen; Y Shoenfeld
Journal:  Circulation       Date:  1996-04-15       Impact factor: 29.690

  8 in total
  2 in total

1.  Aortic valve replacement for aortic regurgitation in a patient with antiphospholipid antibody syndrome.

Authors:  Nozomu Sasahashi; Hisao Harada; Yoshiaki Saji; Akira Marui; Takeshi Nishina; Masashi Komeda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-07

Review 2.  Valvular heart disease in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Olivier Huttin; Shirine Mohamed; Pierre-Yves Marie; Christine Selton-Suty; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.